Wave Life Sciences (WVE) Other Non-Current Liabilities (2014 - 2023)
Wave Life Sciences' (WVE) quarterly Other Non-Current Liabilities came in at $190000.0 in Q2 2023, little changed on a QoQ basis from $190000.0 in Q1 2023.
Analysis
Wave Life Sciences (WVE) Other Non-Current Liabilities (2014 - 2023) Analysis & Trends
Wave Life Sciences (WVE) has 10 years of Other Non-Current Liabilities data on file, last reported at $190000.0 in Q2 2023.
- Quarterly Other Non-Current Liabilities changed N/A year-over-year to $190000.0 in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $190000.0 (changed N/A YoY) and the FY2022 annual result came in at $190000.0, changed N/A from the prior year.
- Other Non-Current Liabilities held at $190000.0 in Q2 2023, from $190000.0 in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $2.0 million in Q1 2019 to a low of $190000.0 in Q4 2022.
- A 5-year average of $1.0 million and a median of $1.0 million in 2021 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2022 — Other Non-Current Liabilities jumped 113.27% — and 2023, when it sank 78.11%.
- Tracing WVE's Other Non-Current Liabilities over 5 years: stood at $1.7 million in 2019, then sank by 72.46% to $474000.0 in 2020, then surged by 113.92% to $1.0 million in 2021, then slumped by 81.26% to $190000.0 in 2022, then changed by 0.0% to $190000.0 in 2023.
- The last three Other Non-Current Liabilities figures came in at $190000.0 (Q2 2023), $190000.0 (Q1 2023), and $190000.0 (Q4 2022), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 10 | Wave Life Sciences | 986.38 Mn | 618.37 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2023 | 190,000.00 |
| Mar 31, 2023 | 190,000.00 |
| Dec 31, 2022 | 190,000.00 |
| Mar 31, 2022 | 868,000.00 |
| Sep 30, 2021 | 1.01 Mn |
| Jun 30, 2021 | 339,000.00 |
| Mar 31, 2021 | 407,000.00 |
| Dec 31, 2020 | 474,000.00 |
| Sep 30, 2020 | 1.42 Mn |
| Jun 30, 2020 | 1.52 Mn |
| Mar 31, 2020 | 1.62 Mn |
| Dec 31, 2019 | 1.72 Mn |
| Sep 30, 2019 | 1.79 Mn |
| Jun 30, 2019 | 1.90 Mn |
| Mar 31, 2019 | 2.04 Mn |
| Dec 31, 2018 | 2.14 Mn |
| Sep 30, 2018 | 1.50 Mn |
| Jun 30, 2018 | 1.53 Mn |
| Mar 31, 2018 | 1.61 Mn |
| Dec 31, 2017 | 1.62 Mn |